Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease
Item
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Files for Download
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967605/pdf/ciw334.pdf
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Document Viewer
Title
Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease
Subject
Description
Ebola virus (EBOV) infection causes a severe and often fatal disease.
An updated was made in Erratum on 2017 July 5.
An updated was made in Erratum on 2017 July 5.
Date
2016-08-15
Type
Citation
McElroy, A. K., J. R. Harmon, T. D. Flietstra, S. Campbell, A. K. Mehta, C. S. Kraft, M. G. Lyon, J. B. Varkey, B. S. Ribner, C. J. Kratochvil, P. C. Iwen, P. W. Smith, R. Ahmed, S. T. Nichol and C. F. Spiropoulou (2016). "Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease." Clin Infect Dis 63(4): 460-467.
Abstract
BACKGROUND: Ebola virus (EBOV) infection causes a severe and often fatal disease. Despite the fact that more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific community still does not have a clear understanding of the mechanisms by which EBOV causes such severe disease. METHODS: In this study, 54 biomarkers in plasma samples serially collected from 7 patients with EVD were analyzed in an attempt to define the kinetics of inflammatory modulators. Two clinical disease groups were defined (moderate and severe) based on the need for clinical support. Biomarkers were evaluated for correlation with viremia and clinical disease in an effort to identify pathways that could be useful targets of therapeutic intervention. RESULTS: Patients with severe disease had higher viremia than those with moderate disease. Several biomarkers of immune activation and control were significantly elevated in patients with moderate disease. A series of pro-inflammatory cytokines and chemokines were significantly elevated in patients with severe disease. CONCLUSIONS: Biomarkers that were associated with severe EVD were proinflammatory and indicative of endothelial or coagulation cascade dysfunction, as has been seen historically in patients with fatal outcomes. In contrast, biomarkers that were associated with moderate EVD were suggestive of a strong interferon response and control of both innate and adaptive responses. Therefore, clinical interventions that modulate the phenotype and magnitude of immune activation may be beneficial in treating EVD.
Accessibility
free online - Pubmed Central
Was this resource helpful?